title: Expression of galectin-7 is induced in breast cancer cells by mutant p53.
abstract: Galectin-7 was initially described as a marker of epithelial differentiation expressed in the stratified epithelium of various tissues. Like other members of the galectin family, its expression level is often significantly altered in cancer cells. In breast cancer, its expression is significantly augmented in aggressive molecular subtypes, most notably in estrogen receptor-negative tumors and in cell lines with a basal-like phenotype. Studies using experimental mouse models have further shown high expression of galectin-7 was sufficient to increase the metastatic behavior of poorly metastatic breast cancer cells, rendering them more resistant to apoptosis. This expression pattern in breast cancer cells is unexpected because galectin-7 was originally identified as a p53-induced gene. To address this paradox, we have examined the molecular mechanisms regulating galectin-7 in breast cancer cells. Our results showed that transfection of breast cancer cells with expression vectors encoding mutant p53 was sufficient to induce galectin-7 at both mRNA and protein levels. Doxorubicin treatment of breast cancer cells harboring a mutant p53 also induced galectin-7. This induction was specific since knockdown of endogenous mutant p53 inhibited doxorubicin-induced galectin-7 expression. The p53-induced galectin-7 expression in breast cancer cells correlated with increased NF-κB activity and was inhibited by NF-κB inhibitors, indicating that the ability of mutant p53 to induce galectin-7 was dependent on NF-κB activity. The implication of NF-κB was further supported by data showing that NF-κB bound to the endogenous galectin-7 promoter and that TNFα-induced galectin-7 expression was abolished by NF-κB inhibitors. Taken together, our data provide an explanation to the observed high galectin-7 expression levels in cancer cells and suggest that galectin-7 could be part of a common pathway used by mutant p53 to promote cancer progression.
authors: Institut National de la Recherche Scientifique, Institut Armand-Frappier, Laval, Québec, Canada.
authors: Carole G
authors: CG
authors: Campion
authors: Marilyne
authors: M
authors: Labrie
authors: Geneviève
authors: G
authors: Lavoie
authors: Yves
authors: Y
authors: St-Pierre
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D037161:Galectins / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D009154:Mutation; D016328:NF-kappa B / Q000378:metabolism; D015533:Transcriptional Activation / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D015854:Up-Regulation / Q000235:genetics
chemical_list: D037161:Galectins; C092525:LGALS7 protein, human; D016328:NF-kappa B; D016159:Tumor Suppressor Protein p53
references: Differentiation. 1998 Jul;63(3):159-68
references: 9697310
references: Oncogene. 2010 May 13;29(19):2795-806
references: 20190799
references: Oncogene. 2000 Mar 2;19(10):1245-56
references: 10713666
references: Mol Biol Cell. 2008 Dec;19(12):5541-9
references: 18829868
references: Pathol Oncol Res. 2010 Dec;16(4):569-77
references: 20177845
references: J Biol Chem. 2002 Feb 1;277(5):3487-97
references: 11706006
references: Oncol Rep. 2012 Dec;28(6):1968-76
references: 22961650
references: Science. 2002 Apr 19;296(5567):550-3
references: 11910072
references: Nat Rev Cancer. 2005 Jan;5(1):29-41
references: 15630413
references: Cancer Invest. 2008 Jul;26(6):615-23
references: 18584353
references: Front Biosci (Landmark Ed). 2012 Jan 01;17:438-50
references: 22201754
references: Oncol Rep. 2010 Aug;24(2):495-500
references: 20596638
references: Mol Biol Cell. 2011 Apr;22(7):999-1013
references: 21289092
references: Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11329-34
references: 10500176
references: Histopathology. 2008 Mar;52(4):483-93
references: 18315601
references: Nature. 2000 Aug 17;406(6797):747-52
references: 10963602
references: Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9090-5
references: 8799159
references: J Cell Biochem. 2004 Jan 1;91(1):118-24
references: 14689585
references: Cancer Res. 1998 Jul 15;58(14):3015-20
references: 9679965
references: Am J Pathol. 2010 Jun;176(6):3023-31
references: 20382700
references: Adv Cancer Res. 2000;77:81-137
references: 10549356
references: Science. 1990 Aug 24;249(4971):912-5
references: 2144057
references: Mol Cell Biochem. 2003 Jan;243(1-2):153-60
references: 12619901
references: Nature. 1997 Sep 18;389(6648):300-5
references: 9305847
references: Mol Cell Biol. 2005 Nov;25(22):10097-110
references: 16260623
references: Ann Oncol. 2007 Jul;18(7):1285-6
references: 17675400
references: Hum Pathol. 2010 Sep;41(9):1220-30
references: 20399482
references: Oncogene. 2007 Apr 2;26(15):2157-65
references: 17401424
references: Carcinogenesis. 1993 May;14(5):833-9
references: 8504475
references: Nature. 2006 May 25;441(7092):431-6
references: 16724054
references: Cancer Res. 2007 Mar 15;67(6):2396-401
references: 17363555
references: BMC Cancer. 2010 Jun 15;10:290
references: 20546628
references: Int J Cancer. 2007 Jun 1;120(11):2331-8
references: 17304502
references: Oncogene. 2009 Feb 19;28(7):1005-15
references: 19079339
references: Cell Mol Life Sci. 2006 Mar;63(6):686-97
references: 16429325
references: Annu Rev Biochem. 2008;77:557-82
references: 18410249